Charles Swift, DO
Internal Medicine · West Plains, MONPI 1609167402
Payments from drug & device makers
Across 64 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$257
- Pfizer$154
- Daiichi Sankyo Inc.$111
- Amgen$110
- Lilly USA, LLC$67
- E.r. Squibb & Sons, L.L.C.$43
- plus $290 from 12 others
What the payments were for
- Food & beverage$1,01899%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $257 |
| Pfizer | 11 | $154 |
| Daiichi Sankyo Inc. | 6 | $111 |
| Amgen | 7 | $110 |
| Lilly USA, LLC | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Boehringer Ingelheim | 3 | $41 |
| Boston Scientific | 2 | $40 |
| AstraZeneca | 2 | $32 |
| Pharmacosmos Therapeutics Inc. | 1 | $28 |
| Dexcom, Inc. | 2 | $27 |
| Abbott | 1 | $25 |
| Bayer | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Novartis | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$1,033 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 900 | $243,889 |
| OzempicSemaglutide | 132 | $151,469 |
| Tresiba Flextouch U-200Insulin Degludec | 132 | $145,588 |
| JardianceEmpagliflozin | 140 | $76,687 |
| FarxigaDapagliflozin Propanediol | 93 | $51,520 |
| Tresiba Flextouch U-100Insulin Degludec | 198 | $48,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $35,646 |
| JanuviaSitagliptin Phosphate | 60 | $24,264 |
| XareltoRivaroxaban | 116 | $23,511 |
| MyrbetriqMirabegron | 65 | $16,566 |
| Budesonide | 83 | $15,061 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 141 | $14,347 |
| Ondansetron Hcl | 155 | $13,714 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $13,353 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 86 | $13,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $154 | $250,961924 claims |
| Novo NordiskOzempic, Fiasp | $257 | $158,168152 claims |
| Boehringer IngelheimJardiance | $41 | $76,687140 claims |
| AstraZenecaFarxiga | $32 | $51,52093 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $16,56665 claims |
| AbbVieLumigan, Linzess | $16 | $12,68835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in West Plains
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.